Mark Corrigan - 02 Jun 2021 Form 4 Insider Report for Nabriva Therapeutics plc

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 02 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2021, 17:50:19 UTC
Next SEC filing: 30 Jul 2021
Source filing: View source filing
Reporting owner signature: /s/ Robert Crotty, by power of attorney

Key filing fact

Mark Corrigan filed Form 4 for Nabriva Therapeutics plc on 04 Jun 2021.

Key facts

This page summarizes Mark Corrigan's Form 4 filing for Nabriva Therapeutics plc.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Jun 2021, 17:50.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBRV transaction Derivative

Share Options

Award

Transaction value: $0
Shares: +10,500
Change %
Price: $0.000000
Shares after: 10,500
Date: 02 Jun 2021
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 10,500
Exercise price: $1.39
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option was granted on June 2, 2021.

Footnote F2

The option will vest over a three-year period on a monthly pro rata basis beginning on June 2, 2021 and subject to the Reporting Person's continued service on the board of directors of the Issuer.